Recent Headlines
AnaSpec Signs Distribution Agreement with Bioeksma UAB
AnaSpec, Inc. and Bioeksma UAB today announced a non-exclusive distributor agreement that will allow Bioeksma UAB to distribute AnaSpec’s catalog and custom products throughout Lithuania and Latvia. AnaSpec’s Director of Sales & Marketing, Violeta Rajkovska, noted, “AnaSpec... - June 05, 2009 - AnaSpec, EGT Group
RayBiotech Now Offers Nearly 500 ELISA Kits
RayBiotech, the Protein Array Pioneer Company, has just increased its product line of different ELISA kits to 495, including ones detecting cytokines, chemokines, growth factors, angiogenic factors and adipokines in human, mouse, and rat samples. - June 03, 2009 - RayBiotech, Inc
AnaSpec Introduces Industry’s First FRET-Based Thrombin Assay Kit
AnaSpec has announced the launch of the industry’s first FRET-based thrombin assay – the SensoLyte 520 Thrombin Activity Assay Kit. Thrombin, a serine protease, plays a central role in hemostasis by converting soluble plasma fibrinogen into an insoluble fibrin clot and by promoting... - May 30, 2009 - AnaSpec, EGT Group
"Stress Free Nation" Campaign from Indigene Initiated in Bahrain
“Stress Free Nation” Campaign from Indigene is designed for Pharmacists and consumers and will educate them about the ways to manage high stress levels. - May 22, 2009 - Indigene Pharmaceuticals
AnaSpec Introduces Line of Membrane Potential Fluorescent Probes
AnaSpec has introduced a wide selection of membrane potential fluorescent probes. The plasma membrane of a cell typically has a transmembrane potential of approximately -70 mV (negative inside) as a consequence of K+, Na+ and Cl– concentration gradients that are maintained by active... - May 20, 2009 - AnaSpec, EGT Group
MedSource Awarded Services Contract for a Phase I Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia Clinical Trial
Houston-based Contract Research Organization (CRO) to manage three-year Phase I study - May 17, 2009 - MedSource
MedSource Awarded Services Contract for a Phase III Epilepsy Clinical Trial
MedSource, a Contract Research Organization (CRO) providing Phase I-IV clinical trials support, announced it has been awarded a service contract to manage a 50-center, multi-national, late phase epilepsy trial. The Houston-based CRO with regional offices in Raleigh, NC, will provide Project... - May 15, 2009 - MedSource
AnaSpec Introduces Biotin Labeled Beta-Amyloid GO™ Peptides
AnaSpec has introduced a line of b-amyloid peptides labeled with biotin (N or C-terminal biotin labels) as well as N-terminal biotin labeled b-amyloid peptides with a fluorescein label on the C-terminus. - May 15, 2009 - AnaSpec, EGT Group
Sustainable Now Technologies Appoints Chief Technology Officer
At a recent press conference, Sustainable Now Technologies (SNT) announced the appointment of their third officer. - May 15, 2009 - Sustainable Now Technologies
Sustainable Now Technologies Launches Website
Green Technologies Corporation, Sustainable Now Technologies (SNT), announces the launch of it's official company website. - May 13, 2009 - Sustainable Now Technologies
AnaSpec Launches Z-Fish™ Antibodies
AnaSpec has announced the launch of the Z-Fish™ product line of antibodies in order to address the growing needs of the research community for zebrafish specific antibodies, peptides and other products. - May 09, 2009 - AnaSpec, EGT Group
Indigene Launches Memoryl in Cyprus
Indigene Pharmaceuticals, A US based bio-pharmaceuticals company, has announced the launch of its highest selling brand Memoryl in Cyprus in association with M S Jacovides group. “We are delighted to launch Memoryl in Cyprus in association with M S Jacovides group and we are sure that our... - May 09, 2009 - Indigene Pharmaceuticals. Pvt. Ltd
Functional Genetics Highlights Progress in the Development of Broad-Spectrum Antiviral at the 22nd International Conference on Antiviral Research
Functional Genetics, Inc. today announced that two platform presentations and three poster abstracts on progress being made in its broad-spectrum antiviral programs will be presented during the International Conference on Antiviral Research in Miami, FL from May 4 to 7. “The development of... - May 06, 2009 - Functional Genetics, Inc.
AnaSpec Introduces New SensoLyte Anti-Human MOG (1-125) IgG ELISA Kit
AnaSpec has announced the release of the newest addition to its Anti-MOG ELISA assay kit series – the SensoLyte Anti-Human MOG (1-125) IgG Quantitation ELISA Kit. This kit, along with previously featured SensoLyte Anti-Mouse MOG (1-125) and SensoLyte Anti-Rat MOG (1-125) IgG ELISA assay kits... - May 03, 2009 - AnaSpec, EGT Group
AnaSpec Launches New Headquarters in Fremont, California
Today AnaSpec announced the launch of its new headquarters in Fremont, California. Rapidly expanding over the past 16 years, AnaSpec has graduated to a state-of-the-art facility designed from the ground up for the very highest levels of lab and R&D production. The 44,010 square foot facility... - April 30, 2009 - AnaSpec, EGT Group
AnaSpec Introduces New HiLyte Fluor™ 594 Labeled Secondary Antibodies & Streptavidin
AnaSpec has introduced a line of secondary antibodies and streptavidin conjugated to the newest member of the HiLyte Fluor™ family - HiLyte Fluor™ 594 (Ex/Em=593/616 nm). Using optimal fluorophore/protein labeling ratio, these HiLyte Fluor™ 594-IgG conjugates exhibit high... - April 15, 2009 - AnaSpec, EGT Group
AnaSpec Introduces New SensoLyte Luminescent Peroxidase Assay Kits
AnaSpec has introduced two new luminescent read-out assay kits for determining peroxidase activity – the SensoLyte Luminescent Peroxidase Assay Kit and the SensoLyte Luminescent Peroxidase ELISA Assay Kit. - April 12, 2009 - AnaSpec, EGT Group
AnaSpec Introduces Series of Cell Penetrating Peptides (CPP)
AnaSpec has CPPs such as (Arg)9, Antennapedia, TAT and others. Offerings include green fluorescent labeled (e.g. FAM or FITC) CPP, red labeled (e.g. TAMRA), Cys conjugated CPPs or Cys(Npys) conjugated CPP. - April 08, 2009 - AnaSpec, EGT Group
MoBiTec GmbH, Germany, is Offering Photochromic Fluorescent Protein EosFP
The Green-to-Red switchable, photochromic Fluorescent Protein „EosFP“ offers advantageous applications in Molecular Cell Biology, and is now available through the German biotech company MoBiTec GmbH. With violet light, single cells in an EosFP marked (green) cell population can be switched to red, so that their fate can be followed selectively, for example in embryonic cell differentiation. Alternatively, a particular compartment within an EosFP marked (green) cell can be switched to red. - March 25, 2009 - MoBiTec GmbH
AnaSpec’s ClearPoint™ Peptides Win Best New Product Award
AnaSpec’s ClearPoint™ Peptides were awarded the Best New Product Award in the category of Biological Samples and Reagents at Cambridge Healthtech Institute's Molecular Medicine Tri-Conference which was held in San Francisco, CA from February 25-27. By spiking protein tryptic digests... - March 25, 2009 - AnaSpec, EGT Group
AnaSpec Offers Calcein AM for Live Cell Staining
AnaSpec is pleased to offer Calcein, AM, a cell-permeant and non-fluorescent compound that is widely used for determining cell viability. Non-fluorescent Calcein, AM in live cells is hydrolyzed by intracellular esterases into the strongly green fluorescent anion calcein, and is retained in the... - March 18, 2009 - AnaSpec, EGT Group
MoBiTec GmbH Closes Distribution Agreement for Lactococcus lactis Gene Expression System with NIZO Food Research
NIZO food research has developed a Gram positive gene expression system making use of Lactococcus lactis and its regulation mechanism for the production of the antibiotic peptide nisin, the NIsin Controlled gene Expression system (NICE). The NICE system is already used as a dedicated expression system by many labs all around the world. With NICE, MoBiTec expands its rich portfolio of non-E. coli based expression systems. - March 15, 2009 - MoBiTec GmbH
AnaSpec Launches New Anti-Keratin 10, 13 and 14 Antibodies
AnaSpec has announced type I acidic keratin antibodies (keratin –10, -13 and -14) have been tested in applications such as western blots or IHC. - March 15, 2009 - AnaSpec, EGT Group
AnaSpec Launches New SensoLyte® Rh110 Long Wavelength Plasmin Activity Assay Kit
AnaSpec is pleased to announce the release of another long wavelength protease assay – the SensoLyte® Rh110 Plasmin Activity Assay Kit (Ex/Em=496 nm/520 nm). - March 14, 2009 - AnaSpec, EGT Group
AnaSpec Signs Distribution Agreement with BioPike, LLC
AnaSpec, Inc. and BioPike, LLC today announced a non-exclusive distributor agreement that will allow BioPike, LLC to distribute AnaSpec’s catalog and custom products throughout China. AnaSpec’s Director of Sales & Marketing, Violeta Rajkovska, noted, “AnaSpec is pleased to... - March 13, 2009 - AnaSpec, EGT Group
MDS Nordion to Demonstrate Improved TheraSphere® Administration System During SIR 2009
MDS Nordion event information for the Society of Interventional Radiology 2009 Scientific Meeting. - March 07, 2009 - MDS Nordion
MDS Nordion to Host Physician Expert Teams from Banner Good Samaritan Medical Center and UNC School of Medicine at SIR 2009
MDS Nordion event information for the Society of Interventional Radiology 2009 Scientific Meeting. - March 07, 2009 - MDS Nordion
Genescient and Kronos Announce Alzheimer's Disease Collaboration
Genescient Corporation and Kronos Science Laboratory will work together to analyze the Kronos Alzheimer's Case-Control Database, considered to be the finest Alzheimer's Disease genetic data set in the US. The companies hope to identify genes previously unrecognized genes that are involved in Alzheimer's Disease. - March 04, 2009 - Genescient Corporation
AnaSpec Introduces Newest GO™ Peptides - Exendins
Along with a host of popular Exendin peptides, AnaSpec’s GO™ Peptides line includes Fluorescein-Trp25-Exendin-4 (FLEX) and [Cys(HiLyteFluor 647 C2 maleimide)]-Exendin-4 - two exendin peptides that are not immediately available anywhere else. - March 01, 2009 - AnaSpec, EGT Group
AnaSpec Introduces Cost-Effective Replacement for Tetramethyl Rhodamine Maleimides
AnaSpec has introduced a collection of Tetramethylrhodamine C2 maleimides that represent an equally effective and more cost-effective replacement for Tetramethyl rhodamine maleimides. - February 27, 2009 - AnaSpec, EGT Group
AnaSpec Introduces Industry’s First NMHC II Antibodies
AnaSpec has announced the release of the industry’s first provider of nonmuscle myosin class II heavy chain (NMHC) antibodies. Nonmuscle myosin class II proteins belong to the superfamily of actin-based motor proteins. They form hexamer structures composed of two ~200kDa heavy chains (NMHC... - February 22, 2009 - AnaSpec, EGT Group
Medi Introduces Mediven® Sheer & Soft: Stylish and Comfortable Compression Therapy Treatments Now Available
Medi USA, a worldwide leader in medical therapy products, introduces Mediven® Sheer & Soft, a complete line of fashionable, discreet and comfortable compression therapy stockings suitable for day and evening wear. Independently proven to be more sheer and comfortable than leading competitors, Sheer & Soft stockings are available in a variety of colors. - February 20, 2009 - Medi USA
AnaSpec Introduces Industry’s Most Sensitive Luminescent Alkaline Phosphatase Assay Kits
AnaSpec announced the release of the industry’s most sensitive assay kits for the detection of alkaline phosphatase activities. The SensoLyteTM Luminescent Alkaline Phosphatase and SensoLyteTM Luminescent Alkaline Phosphatase ELISA assay kits contain a chemiluminescent substrate capable of... - February 19, 2009 - AnaSpec, EGT Group
Grand Opening of Masy Systems’ Biorepository
State of the Art Biorepository Opening in February 2009. - February 18, 2009 - Masy Systems
Anavex Appoints Leading Alzheimer's Disease Expert Dr. Mark Smith to Scientific Advisory Board
Anavex Life Sciences Corp. today announced the appointment of Dr. Mark A. Smith, Ph.D., FRCPath, to its scientific advisory board. - February 12, 2009 - Anavex Life Sciences Corp.
Pediatric Brain Tumor Foundation Boosts Research Funding by $8 Million
The Pediatric Brain Tumor Foundation (PBTF) increased its medical research funding commitments by $8.35 million in 2008. The grants consist of an additional $6 million to the PBTF Institute at Duke University; $1 million to the PBTF Institute at the University of California San Francisco and $1... - February 08, 2009 - Pediatric Brain Tumor Foundation
Anavex Scales Up Synthesis of Anavex 2-73 for Phase 1 Alzheimer’s Disease Study
Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) has signed an agreement with organic chemistry services provider Syntagon AB (“Syntagon”) for the scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is... - February 04, 2009 - Anavex Life Sciences Corp.
AnaSpec Awarded Patent for HiLyte FluorTM Dyes
AnaSpec, Inc. today announced that the U.S. Patent and Trademark Office has issued the company patent number 7,465,810 for “Reactive 1,3’-Crosslinked Carbocyanines and Their Bioconjugates.” - February 01, 2009 - AnaSpec, EGT Group
AnaSpec Introduces SensoLyte™ Anti-MOG (1-125) IgG ELISA Kits - Mouse & Rat
AnaSpec announced the release of 2 new SensoLyteTM Anti-MOG ELISA assay kits – the SensoLyteTM Anti-Mouse MOG (1-125) and SensoLyteTM Anti-Rat MOG (1-125) IgG ELISA Assay Kits. - January 31, 2009 - AnaSpec, EGT Group
AnaSpec Introduces New AnaTagTM HiLyte FluorTM 594 & 680 Protein Labeling Kits
AnaSpec has announced the inclusion of two new dyes in its AnaTagTM protein labeling kit collection - HiLyte FluorTM 594 (Ex/Em=593/616 nm) and HiLyte FluorTM 680 (Ex/Em=678/699 nm). Developed by AnaSpec, HiLyte FluorTM dyes are a series of dyes that spans the whole visible spectrum (Figure... - January 25, 2009 - AnaSpec, EGT Group
AnaSpec Introduces New ClearPointTM beta-Amyloid Peptides
ClearPointTM peptides are AnaSpec’s trademark collection of heavy or stable isotope labeled peptides and amino acids. - January 11, 2009 - AnaSpec, EGT Group
AnaSpec’s Published References Pass 700
The number of published papers that cite AnaSpec’s products has passed 700. - January 09, 2009 - AnaSpec, EGT Group
Researchers Create Smaller, Brighter Probe, Tailored for Clinical Molecular Imaging and Tumor Targeting
Researchers have developed a new generation of microscopic particles for molecular imaging, constituting one of the first promising nanoparticle platforms that may be readily adapted for tumor targeting and treatment in the clinic. According to the investigators at Memorial Sloan-Kettering Cancer... - December 22, 2008 - Hybrid Silica Technologies Inc.
AnaSpec Introduces Line of Fluorescent Probes for Nucleic Acids
AnaSpec carries a variety of premium quality stains, including cell-impermeant and cell-permeant nucleic acid stains. - December 21, 2008 - AnaSpec, EGT Group
University of New Brunswick and AnaSpec Present Poster at ASCB2008
AnaSpec, in collaboration with the U. of New Brunswick and the Natural Sciences and Engineering Research Council of Canada (NSERC), presented a poster entitled, “The Expression and Activity of MMPs during Zebrafish (Danio rerio) Development." - December 20, 2008 - AnaSpec, EGT Group
Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer's Compound ANAVEX 1-41 Published in Journal of Neuropsychopharmacology
Anavex Life Sciences Corp. (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that the anti-amnesic and neuroprotective effects of ANAVEX 1-41 are detailed in a paper... - December 19, 2008 - Anavex Life Sciences Corp.
AnaSpec Introduces Two New IRAK1 Antibodies – pThr 209 & 387
AnaSpec has introduced two new phosphospecific IRAK1 polyclonal antibodies – anti-IRAK1 (pThr 209) and anti-IRAK1 (pThr387). - December 18, 2008 - AnaSpec, EGT Group
Anavex Presents Potent Neuroprotective Effects of Anavex 1-41 at Neuroscience 2008
Anavex Life Sciences Corp., a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, was selected to present its latest results with ANAVEX 1-41 at Neuroscience 2008, the 38th annual meeting of the Society... - December 17, 2008 - Anavex Life Sciences Corp.
AnaSpec Introduces Industry’s First Fluorimetric Assay Kit for Aggrecanase-1 Activity Detection
AnaSpec has announced the release of the industry’s first fluorimetric assay optimized to detect ADAMTS-4 (aggrecanase-1) activity - the SensoLyteTM 520 Aggrecanase-1 Assay Kit. A FRET based assay, it is homogeneous and has an emission in the green range (Ex/Em= 490 nm/520 nm). The kit... - December 17, 2008 - AnaSpec, EGT Group
Functional Genetics, Inc. Announces Agreement with Elanco, a Division of Eli Lilly and Company
Functional Genetics, Inc., a biotechnology research and development company, announced today that it has reached a collaborative research, license and commercialization agreement with Elanco, the animal health division of Eli Lilly and Company. The agreement establishes the framework for... - December 09, 2008 - Functional Genetics, Inc.